(083) Evaluation of a New Antiemesis Protocol to Reduce Hematopoietic Stem Cell Transplant Associated Nausea and Vomiting

Poster Abstract: Background/Rationale: Patients undergoing hematopoietic stem cell transplantation (HSCT) often face gastrointestinal toxicities, particularly nausea and vomiting, which can be more severe during the conditioning chemotherapy. To address these symptoms antiemetic prophylaxis is provided to patients, however, some patients may still experience breakthrough emesis. In such cases, treatment guidelines by the National Comprehensive Cancer Network and the American Society of Clinical Oncology suggest the addition of another antiemetic with a different mechanism of action. The bone marrow transplant program at Ochsner Medical Center has recently established a new protocol for emetic prophylaxis in patients undergoing HSCT by incorporating the latest recommendations from treatment guidelines and clinical trials.

Objective: To evaluate if a new antiemetic regimen protocol significantly reduces the number of patient requests for nausea/vomiting medications during the acute phase of hematopoietic stem cell transplant patients.

Methods: This retrospective study analyzed medical records of adult patients who underwent hematopoietic stem cell transplants at a single center between January 2021 and July 2023. The patients were divided into two groups based on the antiemetic protocol they received: the original protocol from January 2021 to June 2022 and the new protocol from July 2022 to July 2023. The primary goal was to determine the number of breakthrough nausea medication administrations during the acute period of stem cell transplant. Moreover, we evaluated the number of emesis episodes in the delayed period of stem cell transplant and the amount of nausea medication needed to manage nausea and vomiting during this period. Descriptive statistics were used to analyze the data.

Results: Pending/in progress

Discussion/

Conclusion: Pending

References (must also be included in final poster): 1. Atilla E, Ataca Atilla P, Cengiz Seval G, Bektaş M, Demirer T. Current approach to early gastrointestinal and liver complications of hematopoietic stem cell transplantation. Turk J Gastroenterol. 2019;30(2):122-131. doi:10.5152/tjg.2018.18156
2. Yuda S, Fuji S, Savani B, Gatwood KS. Antiemetic Strategies in Patients Who Undergo Hematopoietic Stem Cell Transplantation. Clin Hematol Int. 2022;4(3):89-98. doi:10.1007/s44228-022-00012-8
3. Berger MJ, Ettinger DS, Agarwal R, et al. NCCN Guidelines Insights: Antiemesis, Version 2.2023. J Natl Compr Canc Netw. 2023. Retrieved from https://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf
4. Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: ASCO Guideline Update [published correction appears in J Clin Oncol. 2020 Nov 10;38(32):3825] [published correction appears in J Clin Oncol. 2021 Jan 1;39(1):96]. J Clin Oncol. 2020;38(24):2782-2797. doi:10.1200/JCO.20.01296
5. Clemmons AB, Orr J, Andrick B, Gandhi A, Sportes C, DeRemer D. Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Highly Emetogenic Chemotherapy and Hematopoietic Cell Transplantation Regimens: The FOND-O Trial. Biol Blood Marrow Transplant. 2018;24(10):2065-2071. doi:10.1016/j.bbmt.2018.06.005Trifilio
6. S, Welles C, Seeger K, et al. Olanzapine Reduces Chemotherapy-induced Nausea and Vomiting Compared With Aprepitant in Myeloma Patients Receiving High-dose Melphalan Before Stem Cell Transplantation: A Retrospective Study. Clin Lymphoma Myeloma Leuk. 2017;17(9):584-589. doi:10.1016/j.clml.2017.06.012